Howard J Harrison, Tzeng Ching-Wei D, Smith J Kevin, Eckhoff Devon E, Bynon J Steve, Wang Thomas, Arnoletti J Pablo, Heslin Martin J
Department of Surgery, Section of Surgical Oncology, University of Alabama at Birmingham, Birmingham, Alabama 35243, USA.
Am Surg. 2008 Jul;74(7):594-600; discussion 600-1.
Surgical resection of primary or metastatic tumors of the liver offers patients the best long-term survival. Liver resections may not be appropriate in patients with bilobar metastases, liver dysfunction, or severe comorbidities. Radiofrequency ablation (RFA) is a technique used to destroy unresectable hepatic tumors through thermocoagulation. We retrospectively reviewed a consecutive series of patients undergoing RFA with unresectable hepatic tumors for local recurrence and overall survival. Under an Institutional Review Board-approved protocol, all patients treated with RFA at the University of Alabama at Birmingham from September 1, 1998, to June 15, 2005, were identified. During this time period, 189 lesions in 107 patients were treated with RFA. Patients' charts were retrospectively reviewed. Data is presented as mean +/- SEM. Significance is defined as P < 0.05. Patient demographics revealed 62 per cent males and 38 per cent females with a mean age of 59 (+/- 1) years. Hepatocellular carcinoma (HCC) represented 54 per cent of the tumors treated. Metastatic colorectal cancer represented 22 per cent and the remaining 24 per cent were other metastatic tumors. Overall recurrence rates for all tumors after RFA was 53 per cent. Local recurrence rates for HCC, colorectal cancer, and other metastatic lesions were 27.6 per cent, 29.1 per cent, and 52 per cent, respectively. The morbidity rate for the procedure was 11 per cent. There was one mortality (0.9%) related to RFA. Laparoscopic RFA for HCC in Childs-Pugh Class C cirrhotics (n = 6) resulted in 50 per cent of patients being transplanted with no evidence of disease at a mean follow-up period of 14 months. RFA is a safe and effective way for treating HCC and other unresectable tumors in the liver that are not eligible for hepatic resection. More effective control of systemic recurrence will dictate survival in the majority of patients with metastatic cancers. Local ablation for HCC in cirrhotic patients may be an effective bridge to transplantation. Liver transplantation may still be the most effective long-term treatment for localized HCC.
手术切除肝脏原发性或转移性肿瘤为患者提供了最佳的长期生存机会。对于存在双叶转移、肝功能不全或严重合并症的患者,肝切除术可能并不合适。射频消融(RFA)是一种通过热凝来破坏无法切除的肝脏肿瘤的技术。我们回顾性分析了一系列接受RFA治疗无法切除肝脏肿瘤的患者的局部复发情况和总生存率。根据机构审查委员会批准的方案,确定了1998年9月1日至2005年6月15日在阿拉巴马大学伯明翰分校接受RFA治疗的所有患者。在此期间,107例患者的189个病灶接受了RFA治疗。对患者病历进行了回顾性分析。数据以平均值±标准误表示。显著性定义为P < 0.05。患者人口统计学数据显示,男性占62%,女性占38%,平均年龄为59(±1)岁。肝细胞癌(HCC)占接受治疗肿瘤的54%。转移性结直肠癌占22%,其余24%为其他转移性肿瘤。RFA治疗后所有肿瘤的总体复发率为53%。HCC、结直肠癌和其他转移性病灶的局部复发率分别为27.6%、29.1%和52%。该手术的发病率为11%。有1例死亡(0.9%)与RFA相关。Childs-Pugh C级肝硬化患者(n = 6)的HCC腹腔镜RFA治疗结果显示,在平均14个月的随访期内,50%的患者接受了移植且无疾病证据。RFA是治疗HCC和其他无法切除且不符合肝切除条件的肝脏肿瘤的一种安全有效的方法。更有效地控制全身复发将决定大多数转移性癌症患者的生存情况。肝硬化患者的HCC局部消融可能是移植的有效桥梁。肝移植可能仍然是局限性HCC最有效的长期治疗方法。